Inactive Instrument

Orchid Pharma Limited Share Price Bombay S.E.

Equities

524372

INE191A01019

Pharmaceuticals

Sales 2024 * 844.53Cr 10Cr Sales 2025 * 1.08TCr 13Cr Capitalization 5.56TCr 67Cr
Net income 2024 * 91Cr 1.09Cr Net income 2025 * 142.2Cr 1.71Cr EV / Sales 2024 * 6.46 x
Net cash position 2024 * 105.6Cr 1.27Cr Net cash position 2025 * 119.7Cr 1.44Cr EV / Sales 2025 * 5.05 x
P/E ratio 2024 *
60.8 x
P/E ratio 2025 *
39.3 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 26.03%
More Fundamentals * Assessed data
Dynamic Chart
Orchid Pharma Limited Appoints Shubha Singh as Additional Director CI
Orchid Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Orchid Pharma Limited Announces Resignation of Mudit Tandon as Independent Director CI
Orchid Pharma Receives United States Food and Drug Administration Approval for Its Novel Invention CI
Transcript : Orchid Pharma Limited, Q3 2024 Earnings Call, Feb 09, 2024
Orchid Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
European Medicines Agency Grants Approval for Orchid Pharma's 'Exblifep' CI
Orchid Pharma Limited Appoints Kapil Dayya as Company Secretary & Compliance Officer CI
Orchid Pharma Limited Announces Resignation of Marina Peter as Company Secretary and Compliance Officer CI
Orchid Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Orchid Pharma Limited Approves the Appointment of Mr. Arjun Dhanuka as Additional Director (In Capacity of Non-Executive & Non-Independent) CI
Orchid Pharma Ties Up with GARDP to Manufacture Antibiotic for Certain Gram-Negative Infections MT
Orchid Pharma Limited Enters into Manufacturing Sub License Agreement with Global Antibiotic Research & Development Partnership CI
Orchid Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Orchid Pharma Raises INR4 Billion Via Qualifed Institutional Placement MT
More news
Managers TitleAgeSince
Chief Executive Officer 56 31/20/31
Director of Finance/CFO - 29/20/29
Compliance Officer - 16/12
Members of the board TitleAgeSince
Chairman 74 31/20/31
Director/Board Member 42 31/20/31
Chief Executive Officer 56 31/20/31
More insiders
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of integrated active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.
More about the company